OR WAIT null SECS
April 12, 2024
The agency’s risk assessment committee has concluded that available evidence has not been found that supports a causal association between glucagon-like peptide-1 receptor agonists and self-harming thoughts and actions.
March 30, 2024
The company is voluntarily recalling the product for potential super potent bottles due to overfilling.
March 22, 2024
The company is recalling one lot of the product because of the potential presence of silicone particulates.
February 21, 2024
FDA's Drug Safety Priorities FY23 describes the center’s key safety programs and activities involved in promoting and protecting public health.
February 12, 2024
The agency’s safety committee stressed the risk of potential adverse reactions involved with taking Paxlovid (nirmatrelvir, ritonavir) in combination with certain immunosuppressants.
January 29, 2024
The company issued the recall because of a package mislabeling problem.
January 17, 2024
The agency is reviewing data on secondary malignancies related to T-cells for approved CAR T-cell medicines.
January 15, 2024
The European Medicines Agency safety committee says there is a potential risk of neurodevelopment disorders in children born to men treated with valproate.
January 09, 2024
The potential for superpotent drug initiated the voluntary recall.
December 11, 2023
The product is being voluntarily recalled because of powder leakage due to seal integrity issues.